Form 4: Cadrenal Therapeutics Director Acquires Stock Options

A director of Cadrenal Therapeutics, Inc. acquired 20,000 stock options on January 23, 2025.

Summary

• John Raymond Murphy, a director at Cadrenal Therapeutics, Inc., acquired 20,000 stock options on January 23, 2025.
• The options have an exercise price of $19.79.
• The options vest pro rata on a monthly basis over 12 months, starting February 1, 2025.
• The options expire on January 22, 2035.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of a stock option grant to a director, which is neither positive nor negative in itself. It is a neutral event.

Positives

• The acquisition of stock options by a director may indicate confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's securities. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies as part of their compensation and incentive programs.
• The vesting schedule of 12 months is also a typical arrangement to align the director's interests with the long-term performance of the company.
• The exercise price of $19.79 is specific to Cadrenal Therapeutics and would need to be compared to other similar companies to assess its relative value.

Stakeholder Impact

• The stock option grant may have a minor positive impact on shareholder sentiment as it aligns the director's interests with the company's performance.

Key Dates

Keywords

stock options, insider trading, Cadrenal Therapeutics, director, equity, CVKD